Literature DB >> 21969085

Favorable outcome of secondary axillary dissection in breast cancer patients with axillary nodal relapse.

Shih-Che Shen1, Chien-Hung Liao, Yung-Feng Lo, Hsiu-Pei Tsai, Wen-Lin Kuo, Chi-Chang Yu, Tzu-Chieh Chao, Miin-Fu Chen, Hsien-Kun Chang, Yung-Chang Lin, Wen-Chi Shen, Shir-Hwa Ueng, Li-Yu Lee, Swei Hsueh, Yi-Ting Huang, Shin-Cheh Chen.   

Abstract

PURPOSE: Little evidence can be found about the long-term outcome of breast cancer patients after axillary lymph node recurrence (ALNR) and its survival benefit after different kinds of management. The present study intends to evaluate the risk factors associated with axillary recurrence after definite surgery for primary breast cancer. The prognosis after ALNR and particularly outcome of different management methods also were studied.
METHODS: We retrospectively reviewed data from 4,473 patients who were diagnosed with primary breast cancer and received surgical intervention in a single institute from January 1990 to December 2002. Medical files were reviewed and data on survival were updated annually. Risk factors and prognosis of patients with axillary recurrence were analyzed. Breast-cancer-specific survival of patients with ALNR and outcomes after different management methods also were studied.
RESULTS: After a median follow-up of 70.2 months, axillary recurrence developed in 0.8% of patients. Factors associated with ALNR included: age younger than 40 years, medial tumor location, no initial standard level I & II axillary dissection, and not receiving hormonal therapy. The 5-year breast-cancer-specific survival after ALNR was 57.9%. For patients who received further axillary dissection, the 5-year survival rate was 82.5% compared with 44.9% for patients who did not receive further dissection.
CONCLUSIONS: ALNR is a rare event in treating breast cancer. Young age at diagnosis and medially located tumor are associated with higher risk, but standardized initial axillary dissection to level II and adjuvant hormonal therapy is protective against ALNR. In patients with ALNR, the outcome is not dismal and survival may be improved if further axillary dissection is given.

Entities:  

Mesh:

Year:  2011        PMID: 21969085     DOI: 10.1245/s10434-011-2082-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Klotho promoter methylation status and its prognostic value in ovarian cancer.

Authors:  Maryam H Al-Zahrani; Fatimah M Yahya; Mourad Assidi; Ashraf Dallol; Abdelbaset Buhmeida
Journal:  Mol Clin Oncol       Date:  2021-07-03

2.  Predictive Value of Molecular Subtyping for Locoregional Recurrence in Early-Stage Breast Cancer with N1 without Postmastectomy Radiotherapy.

Authors:  Ge Wen; Jin-Shan Zhang; Yu-Jing Zhang; Yu-Jia Zhu; Xiao-Bo Huang; Xun-Xing Guan
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

3.  Changes in the Ki-67 labeling index between primary breast cancer and metachronous metastatic axillary lymph node: A retrospective observational study.

Authors:  Naoya Ishibashi; Haruna Nishimaki; Toshiya Maebayashi; Masaharu Hata; Keita Adachi; Kenichi Sakurai; Shinobu Masuda; Masahiro Okada
Journal:  Thorac Cancer       Date:  2018-10-29       Impact factor: 3.500

Review 4.  Loco-regional therapy for isolated locoregional lymph node recurrence of breast cancer: focusing on surgical treatment with combined therapy.

Authors:  Kaori Terata; Ayuko Yamaguchi; Ayano Ibonai; Kazuhiro Imai; Akiyuki Wakita; Yusuke Sato; Satoru Motoyama; Yoshihiro Minamiya
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.